Study of Fosmidomycin and Clindamycin for Malaria Treatment
Author Information
Author(s): Ruangweerayut Ronnatrai, Looareesuwan Sornchai, Hutchinson David, Chauemung Anurak, Banmairuroi Vick, Na-Bangchang Kesara
Primary Institution: Mae Sot Hospital, Tak Province, Thailand
Hypothesis
The study investigates the pharmacokinetics of fosmidomycin when combined with clindamycin at two different dosage regimens in patients with acute uncomplicated falciparum malaria.
Conclusion
The combination of fosmidomycin (900 mg) and clindamycin (300–600 mg) administered every six hours for a minimum of five days could result in a cure rate greater than 95%.
Supporting Evidence
- Both regimens were well tolerated with no serious adverse events.
- The 28-day cure rates for Group I and Group II were 91.3% and 89.7%, respectively.
- Steady-state plasma concentrations of fosmidomycin and clindamycin were attained at about 24 hr after the first dose.
- Marked differences in the pharmacokinetic profiles of fosmidomycin and clindamycin were observed between the two regimens.
Takeaway
This study looked at how two different doses of a malaria treatment worked in patients, finding that the way you take the medicine can really change how well it works.
Methodology
Patients were treated with two different dosage regimens of fosmidomycin and clindamycin over three days, and pharmacokinetic parameters were analyzed.
Potential Biases
Potential biases may arise from the open-label design and the uncontrolled nature of the trial.
Limitations
The study was conducted in a specific geographic area, which may limit the generalizability of the findings.
Participant Demographics
80 patients, 77 males and 3 females, aged 15-61 years, from various ethnic groups.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website